Efficacy and Safety of Wuling Powder in the Treatment of Patients with Diabetic Nephropathy: A Systematic Review and Meta-Analysis

作者：Yunyi Yang, Wenjun Sha, Keke Hou, Yuanying Xu, Shufa Tan, Hongping Yin, Lin Chen, Tao Lei · 发表于：Evidence-based Complementary and Alternative Medicine · 年份：2022 · DOI：10.1155/2022/1720749 · 被引用次数：10 · 研究领域：Nephrotoxicity and Medicinal Plants、Chronic Kidney Disease and Diabetes、Antioxidants, Aging, Portulaca oleracea

Background. Wuling powder is a classical formula of traditional Chinese medicine (TCM), which is extensively applied to treat diabetic nephropathy (DN). However, there are no related reports on systematically evaluating the efficacy of Wuling powder in the treatment of DN. Targeted at this, this study was developed. Materials and Methods. This study systematically searched related articles from nine databases, including PubMed, Cochrane Library, Embase, Web of Science, China Knowledge Infrastructure (CNKI), China Biomedical CD-ROM (Sino Med), Wanfang database, Vipers database (VIP), and the China Clinical Trials Registry website. The randomized controlled trials (RCTs) involving Wuling Power to treat DN were included, which were published from the established data of the above databases to March 2022. In addition, the language of the studies was not restricted. Studies were meta-analyzed using the RevMan 5.4 software given in the Cochrane Collaboration Network. The treatment efficacy was measured using the weighted mean differences (WMD) and 95% confidence intervals (CI). Results. 24 studies were included for the final analysis. 24 h urine volume (WMD = 357.95; 95% CI [322.83, 393.06], p < 0.00001 ), 24 h urine protein quantification(24 h UPQ) (WMD = −1.30; 95% CI [−1.82, −0.78], p < 0.00001 ), serum creatinine (Scr) (WMD = −10.17; 95% CI [−11.13, −9.21], p < 0.00001 ), blood urea nitrogen (BUN) (WMD = −1.62; 95% CI [−2.30, −0.93], p ...